February 25, 2008—InteKrin Therapeutics, Inc., a privately-held clinical stage biopharmaceutical company focused on the development and commercialization of novel drugs for the treatment of diabetes, obesity and metabolic disease, announced that it has initiated a Phase 2b study in diabetic patients with its lead product candidate INT131, a non-TZD SPPARM (Selective Peroxisome Proliferator-Activated Receptor Modulator)...InteKrin Therapeutics' Press Release-
Showing posts with label InteKrin. Show all posts
Showing posts with label InteKrin. Show all posts
Tuesday, February 26, 2008
InteKrin Therapeutics' INT131, Phase IIb study in Type 2 diabetes
February 25, 2008—InteKrin Therapeutics, Inc., a privately-held clinical stage biopharmaceutical company focused on the development and commercialization of novel drugs for the treatment of diabetes, obesity and metabolic disease, announced that it has initiated a Phase 2b study in diabetic patients with its lead product candidate INT131, a non-TZD SPPARM (Selective Peroxisome Proliferator-Activated Receptor Modulator)...InteKrin Therapeutics' Press Release-
Subscribe to:
Posts (Atom)
